This project was completed by Intensity. Intensity joined Secretariat on February 1, 2023.
A generic drug company filed an Abbreviated New Drug Application (ANDA) seeking approval to sell a generic version of a branded sedative drug prior to the expiration of patents covering the branded drug. The generic drug company also filed paragraph IV certification, asserting that the patents covering the branded drug were invalid as obvious. In response, the branded drug company filed claims of patent infringement against the generic drug company.
Intensity performed an evaluation of the commercial success of the branded sedative drug and the patents-in-suit. Intensity determined whether the commercial performance of branded drug was attributable to the patents-in-suit or other economic factors, and whether such performance was commercially successful.
Intensity analyzed sales and economic profits of the branded drug. We evaluated those sales and profits in an appropriate economic context by defining a relevant market and comparing sales of the branded drug to relevant benchmarks.
87 Secretariat Professionals Named in Lexology Index 2025 Consulting Expert Reports
Secretariat is pleased to share that 87 of our experts have been named in the Lexology Index 2025 Consulting Expert Reports series, achieving recognition as global industry leaders across several key categories.
CPSC Redirects Lithium-Ion Battery Rulemaking for Micromobility Products
Regulatory updates don’t always make headlines, but they can shape the future of industries. The CPSC’s recent procedural move on lithium-ion battery safety for micromobility products is a perfect example. Sam Madden breaks down the latest developments in a short summary.
Shalabh Gupta and Amran Nawaz, Associate Directors in Secretariat’s Global Sports Consulting practice, were recently quoted in an S&P Global article discussing sports team acquisition and valuation trends.